EN | UA
EN | UA

Help Support

Back

Safety and efficacy of PrabotulinumtoxinA Injection established for the treatment of cervical and shoulder girdle myofascial pain syndrome

Safety and efficacy of PrabotulinumtoxinA Injection established for the treatment of cervical and shoulder girdle myofascial pain syndrome Safety and efficacy of PrabotulinumtoxinA Injection established for the treatment of cervical and shoulder girdle myofascial pain syndrome
Safety and efficacy of PrabotulinumtoxinA Injection established for the treatment of cervical and shoulder girdle myofascial pain syndrome Safety and efficacy of PrabotulinumtoxinA Injection established for the treatment of cervical and shoulder girdle myofascial pain syndrome

What's new?

PrabotulinumtoxinA injections significantly improve pain scores and health related quality of life of patients suffering from cervical and shoulder gridle myofascial pain syndrome.

PrabotulinumtoxinA injections found to significantly reduce the pain and Neck Disability Index scores among patients with shoulder girdle and cervical myofascial pain syndrome, as per research carried out at The Catholic University of Korea. Myofascial pain syndrome is a well-known painful infirmity. Prior studies assessing the effectiveness of botulinum toxin for the myofascial pain syndrome treatment are inadequate, with variable outcomes. Therefore, this prospective study was conducted to examine the efficacy and safety of direct injection of Prabotulinumtoxin A into painful muscle groups for shoulder girdle and cervical myofascial pain syndrome. A total of 12 patients with shoulder and neck pain were administered with PrabotulinumtoxinA injection. In the mid belly, painful muscles holding trigger points were injected. The tolerability, pain intensity, quality of life and safety were measured at baseline, 6 and 12 weeks after the treatment. 

At 12 weeks, PrabotulinumtoxinA exhibited a considerable reduction in pain intensity. As compared to baseline, 41.7% patients responded well to PrabotulinumtoxinA and experienced 30% reduction in pain at six weeks. However, patients exhibited considerable improvement in the Neck Disability Index scores both at 6 and 12 weeks after the treatment. The study observed no adverse events. At 12 weeks, a significant improvement in health related quality of life and pain scores was noted with prabotulinumtoxinA injection into persistent painful muscles connected with shoulder girdle and cervical myofascial pain syndrome. Injections showed significant tolerability. On the basis of these findings, PrabotulinumtoxinA could be an effective approach to manage myofascial pain syndrome; however, these are the preliminary findings, more investigation should carefully examine using randomized, controlled, prospective trials.

 

Source:

Toxins

Article:

Safety and Efficacy of Prabotulinumtoxin A (Nabota®) Injection for Cervical and Shoulder Girdle Myofascial Pain Syndrome: A Pilot Study.

Authors:

Da-ye Kim, Jae Min Kim

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: